Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study Evaluating the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)

NCT03608657 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03608657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03608657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study Evaluating the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
July 31, 2018
Completion date
March 30, 2022
Enrollment
102 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic